ITGA2B

Across TCGA pan-cancer cohorts, ITGA2B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITGA2B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ITGA2B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ITGA2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, BRCA, and ESCA are the cancer types where ITGA2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.937	0.299	.004	36	view →
BRCA	OS	Median	All	0.096	0.578	.005	24	view →
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
HNSC	OS	Median	All	0.289	0.688	.032	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
COAD	DFS	Median	All	0.941	0.775	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITGA2B–UCEC (DFS)

Open the UCEC breakdown →